MarketPeel
Insider Trading Intelligence
SM

Stephen Machatha

ALDX
CHIEF DEVELOPMENT OFFICER · ALDEYRA THERAPEUTICS, INC. · CIK 0001836354
FILING MIX · LIFETIME62%/38%
BUYS
8
SELLS
5
TOTAL VALUE
$324.8K
COMPANIES
1
ACTIVE SINCE
Apr 2021
HOLDINGS NOW
221,799
AVG SELL PX
$4.09
TRADE KIND
SHOWING 13 / 13
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
4 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Stephen Machatha, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d4+50.00%-0.63%+1.71%-2.34%-1.40%
14d4+50.00%+2.55%+2.22%+0.34%+2.67%
30d4+0.00%+28.26%+1.99%+26.27%+28.13%
60d4+0.00%+14.29%+3.75%+10.55%+8.92%
90d4+25.00%+15.29%+7.21%+8.08%+8.47%
180d4+0.00%+53.87%+8.69%+45.18%+46.86%
1y4(1 pending)+0.00%+86.02%+13.77%+72.24%+102.80%
2y4(2 pending)+0.00%+53.70%+32.66%+21.05%+21.05%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ALDX · 221,799 shares · as of Aug 11, 2025
0101,363202,725304,088405,4502022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
FLOW · 8 buys / 5 sellsCOVERAGE · 18 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALDX
ALDEYRA THERAPEUTICS, INC.
SALE
Chief Development Officer
22,073$5.15$113.7K221,799Aug 11, 2025Aug 13, 2025View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
202,427202,427Mar 4, 2025Mar 6, 2025View →
ALDX
ALDEYRA THERAPEUTICS, INC.
SALE
Chief Development Officer
16,041$4.74$76.0K236,771Aug 12, 2024Aug 14, 2024View →
ALDX
ALDEYRA THERAPEUTICS, INC.
SALE
Chief Development Officer
11,537$3.16$36.5K252,812Mar 12, 2024Apr 17, 2024View →
ALDX
ALDEYRA THERAPEUTICS, INC.
SALE
Chief Development Officer
11,537$3.16$36.5K243,495Mar 12, 2024Mar 12, 2024View →
ALDX
ALDEYRA THERAPEUTICS, INC.
SALE
Chief Development Officer
18,231$3.41$62.1K255,032Mar 11, 2024Mar 12, 2024View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
405,450405,450Mar 9, 2024Mar 12, 2024View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
220,258220,258Feb 28, 2023Mar 2, 2023View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
185,605273,263Jul 15, 2022Jul 19, 2022View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
69,47369,473Jul 15, 2022Jul 19, 2022View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
250,000250,000Mar 30, 2022Apr 1, 2022View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
64,39587,658Mar 30, 2022Apr 1, 2022View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
116,201116,201Apr 12, 2021Apr 14, 2021View →
Other insiders · ALDX
Loading peer insiders…
About this filer
CIK 0001836354
ROLE
Chief Development Officer
PRIMARY
ALDX
COMPANIES
1
ACTIVE SINCE
Apr 2021
MARKETPEEL · /INSIDER/0001836354DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback